MNOVNasdaqPharmaceutical PreparationsFiscal year ends December 31
MEDICINOVA INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.40−0.02 (-1.41%)
Close on Oct 19, 2026
- Market cap
- $68.91M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
10.5%
5M of 49M shares
Institutional holders
29
3 new, 4 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 1 sales
Net sold $1.73M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| 3D Investment Partners Pte. Ltd. | 4,862,047 | 9.90% | 13D (active) amendment | Sep 25, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MNOV | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Essex Woodlands Management, Inc. | 1,105,941 | 2.25% | $1.46M | – | 0.57% |
| BlackRock, Inc. | 752,091 | 1.53% | $992.76K | +46,137 | 0.00% |
| Citigroup Inc | 635,715 | 1.29% | $839.14K | – | 0.00% |
| Vanguard Capital Management LLC | 609,052 | 1.24% | $803.95K | −1,987 | 0.00% |
| Geode Capital Management, LLC | 539,312 | 1.10% | $712.09K | −4,531 | 0.00% |
| Vanguard Fiduciary Trust Co | 282,608 | 0.57% | $373.04K | +1,987 | 0.00% |
| UBS Group AG | 222,200 | 0.45% | $293.30K | – | 0.00% |
| Renaissance Technologies LLC | 205,400 | 0.42% | $271.13K | +15,500 | 0.00% |
| State Street Corp | 193,698 | 0.39% | $255.68K | – | 0.00% |
| Northern Trust Corp | 143,665 | 0.29% | $189.64K | +10,502 | 0.00% |
| Bank of New York Mellon Corp | 78,277 | 0.16% | $103.33K | – | 0.00% |
| Charles Schwab Investment Management Inc | 71,506 | 0.15% | $94.39K | – | 0.00% |
| Bridgeway Capital Management, LLC | 56,031 | 0.11% | $73.96K | – | 0.00% |
| SBI Securities Co., Ltd. | 51,479 | 0.10% | $67.95K | +6,603 | 0.00% |
| Dimensional Fund Advisors LP | 50,552 | 0.10% | $66.73K | – | 0.00% |
| Barclays PLC | 42,806 | 0.09% | $56.50K | −120,094 | 0.00% |
| Schonfeld Strategic Advisors LLC | 36,157 | 0.07% | $47.73K | −219 | 0.00% |
| Susquehanna International Group, Llp | 26,752 | 0.05% | $35.31K | −17,174 | 0.00% |
| Jane Street Group, LLC | 15,818 | 0.03% | $20.88K | −71,267 | 0.00% |
| Vanguard Global Advisers, LLC | 15,599 | 0.03% | $20.59K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 29 | 5M | 10.5% | 3 / 5 | 8 / 4 | 0M | 0M |
| Q1 2026 | 30 | 5M | 11.0% | 5 / 8 | 9 / 7 | 1M | 0M |
| Q4 2025 | 33 | 5M | 10.7% | 9 / 8 | 9 / 2 | 0M | 0M |
| Q3 2025 | 26 | 5M | 10.4% | 4 / 8 | 6 / 1 | 0M | 0M |
| Q2 2025 | 23 | 5M | 10.5% | 0 / 4 | 9 / 5 | 0M | 0M |
| Q1 2025 | 28 | 5M | 10.6% | 2 / 7 | 10 / 4 | 0M | 0M |
| Q4 2024 | 30 | 5M | 10.6% | 5 / 11 | 5 / 5 | 0M | 0M |
| Q3 2024 | 30 | 5M | 10.0% | 4 / 5 | 11 / 6 | 1M | 0M |
| Q2 2024 | 33 | 5M | 9.7% | 5 / 2 | 15 / 7 | 0M | 0M |
| Q1 2024 | 35 | 5M | 9.6% | 5 / 7 | 12 / 4 | 0M | 0M |
| Q4 2023 | 34 | 5M | 10.1% | 6 / 10 | 8 / 2 | 0M | 0M |
| Q3 2023 | 30 | 5M | 10.2% | 3 / 5 | 12 / 7 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of MNOV | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 609,052 | 1.24% | $803.95K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 255,141 | 0.52% | $346.99K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 158,976 | 0.32% | $209.85K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 87,575 | 0.18% | $119.10K | 0.00% | May 31, 2026 |
| Schwab Total Stock Market Index Fund | 71,506 | 0.15% | $95.10K | 0.00% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 68,406 | 0.14% | $93.03K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 50,247 | 0.10% | $66.33K | 0.04% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 25,966 | 0.05% | $35.31K | 0.00% | May 31, 2026 |
| Small Cap Core Fund | 13,894 | 0.03% | $18.34K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 10,525 | 0.02% | $13.89K | 0.01% | Jun 30, 2026 |
| LVIP Dimensional U.S. Core Equity 2 Fund | 6,693 | 0.01% | $8.83K | 0.00% | Jun 30, 2026 |
| AST Small-Cap Equity Portfolio | 4,930 | 0.01% | $6.51K | 0.00% | Jun 30, 2026 |
| JNL/DFA U.S. Small Cap Fund | 3,000 | 0.01% | $3.96K | 0.00% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 100 | 0.00% | $132 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Yuichi Iwaki | President and CEO | 1,091,933 | 2.22% | Jan 20, 2026 |
| Kazuko Matsuda | Chief Medical Officer | 322,996 | 0.66% | Jan 20, 2026 |
| Hideki Nagao | Director | 0 | – | Jun 25, 2026 |
| Carolyn Beaver | Director | – | – | Jun 25, 2026 |
| Nicole Lemerond | Director | – | – | Jun 25, 2026 |
| Opportunity Master Fund 3D | – | 4,862,047 | 9.88% | Sep 29, 2026 |
| Investment Partners Pte. Ltd. 3D | – | – | – | Sep 29, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Opportunity Master Fund 3D – | Sep 25, 2026 | Sale | −640,000 | $2.70 | $1.73M | 4,862,047 |
| Hideki Nagao Director | Nov 28, 2022 | Sale | −6,754 | $2.25 | $15.20K | 0 |
| Hideki Nagao Director | Nov 22, 2022 | Sale | −218 | $2.13 | $464 | 6,754 |
| Hideki Nagao Director | Nov 21, 2022 | Sale | −5,365 | $2.18 | $11.70K | 6,972 |
| Hideki Nagao Director | Nov 17, 2022 | Sale | −309 | $2.18 | $674 | 12,337 |
| Kazuko Matsuda Chief Medical Officer, Director | Aug 23, 2021 | Option exercise | +60,000 | $2.30 | $138.00K | 322,996 |
| Yuichi Iwaki President and CEO, Director | Jul 9, 2021 | Option exercise | +39,583 | $2.54 | $100.54K | 966,933 |
| Kazuko Matsuda Chief Medical Officer, Director | Jun 24, 2021 | Option exercise | +46,554 | $2.54 | $118.25K | 206,746 |
| Kazuko Matsuda Chief Medical Officer, Director | Jun 24, 2021 | Option exercise | +56,250 | $2.46 | $138.38K | 262,996 |
| Geoffrey OBrien Vice President | May 19, 2021 | Option exercise | +11,318 | $2.46 | $27.84K | 48,318 |
| Geoffrey OBrien Vice President | May 19, 2021 | Option exercise | +32,000 | $2.54 | $81.28K | 37,000 |
| Hideki Nagao Director | Mar 11, 2021 | Sale | −2,354 | $7.40 | $17.42K | 12,646 |
| Yuichi Iwaki President and CEO, Director | Feb 25, 2021 | Option exercise | +86,250 | $2.46 | $212.18K | 927,350 |
| Hideki Nagao Director | Sep 15, 2020 | Sale | −1,000 | $5.78 | $5.78K | 15,000 |
| Hideki Nagao Director | Aug 6, 2020 | Option exercise | +15,000 | $2.58 | $38.70K | 16,000 |
| Kazuko Matsuda Chief Medical Officer, Director | Jun 12, 2020 | Option exercise | +20,000 | $5.13 | $102.60K | 160,192 |
| Yuichi Iwaki President and CEO, Director | Apr 8, 2020 | Option exercise | +60,417 | $2.54 | $153.46K | 841,100 |
| Kazuko Matsuda Chief Medical Officer, Director | Apr 8, 2020 | Option exercise | +28,446 | $2.54 | $72.25K | 140,192 |
| Kazuko Matsuda Chief Medical Officer, Director | Mar 13, 2020 | Buy | +2,000 | $3.62 | $7.24K | 111,746 |
| Kazuko Matsuda Chief Medical Officer, Director | Mar 13, 2020 | Buy | +2,000 | $3.62 | $7.24K | 111,476 |
| Yuichi Iwaki President and CEO, Director | Mar 12, 2020 | Buy | +20,000 | $3.10 | $62.00K | 780,683 |
| Kazuko Matsuda Chief Medical Officer | Jun 12, 2019 | Option exercise | +37,000 | $4.80 | $177.60K | 109,457 |
| Hideki Nagao Director | May 13, 2019 | Option exercise | +1,000 | $2.77 | $2.77K | 1,000 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +42,500 | $4.10 | $174.25K | 460,530 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +80,000 | $4.10 | $328.00K | 418,030 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +105,000 | $2.64 | $277.20K | 565,530 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +120,000 | $3.91 | $469.20K | 835,530 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +30,000 | $3.91 | $117.30K | 715,530 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +15,000 | $3.24 | $48.60K | 580,530 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +100,000 | $6.10 | $610.00K | 935,530 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +105,000 | $7.00 | $735.00K | 1,040,530 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +35,700 | $7.34 | $262.04K | 189,280 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +85,000 | $2.54 | $215.90K | 274,280 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +63,750 | $2.46 | $156.83K | 338,030 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +105,000 | $3.09 | $324.45K | 685,530 |
| Masatsune Okajima VP and Head of Japanese Office | Jan 9, 2019 | Option exercise | +41,250 | $2.20 | $90.75K | 153,580 |
| Yuichi Iwaki President and CEO, Director | Jan 3, 2019 | Option exercise | +18,572 | $2.20 | $40.86K | 759,392 |
| Yuichi Iwaki President and CEO, Director | Mar 5, 2018 | Option exercise | +50,003 | $2.20 | $110.01K | 740,594 |
| Yuichi Iwaki President and CEO, Director | Jan 3, 2018 | Option exercise | +53,363 | $4.42 | $235.86K | 690,591 |
| Masatsune Okajima VP and Head of Japanese Office | Dec 12, 2017 | Option exercise | +48,000 | $4.42 | $212.16K | 108,941 |
| Yuichi Iwaki President and CEO, Director | Nov 2, 2017 | Option exercise | +21,067 | $4.42 | $93.12K | 637,228 |
| Yoshio Ishizaka Director | Aug 21, 2017 | Buy | +5,000 | $5.17 | $25.85K | 10,000 |
| Yutaka Kobayashi Director | May 15, 2017 | Buy | +1,000 | $5.60 | $5.60K | 25,000 |
| Yutaka Kobayashi Director | May 12, 2017 | Buy | +24,000 | $5.62 | $134.88K | 24,000 |
| Yutaka Kobayashi Director | Sep 15, 2016 | Buy | +11,800 | $6.44 | $75.99K | 81,800 |
| Yutaka Kobayashi Director | Sep 9, 2016 | Buy | +10,000 | $6.67 | $66.70K | 70,000 |
| Geoffrey OBrien Vice President | Jul 5, 2016 | Option exercise | +3,300 | $4.80 | $15.84K | 8,300 |
| Geoffrey OBrien Vice President | Jul 5, 2016 | Sale(10b5-1 plan) | −3,300 | $8.00 | $26.40K | 5,000 |
| Kazuko Matsuda Chief Medical Officer | Mar 14, 2016 | Option exercise | +800 | $3.56 | $2.85K | 62,003 |
| Masatsune Okajima VP and Head of Japanese Office | Mar 14, 2016 | Option exercise | +8,400 | $3.56 | $29.90K | 51,138 |
| Yutaka Kobayashi Director | Dec 10, 2014 | Buy | +12,000 | $3.54 | $42.48K | 60,000 |
| Yutaka Kobayashi Director | Nov 26, 2014 | Buy | +10,000 | $3.07 | $30.70K | 48,000 |
| Yutaka Kobayashi Director | Nov 20, 2014 | Buy | +13,000 | $3.19 | $41.47K | 38,000 |
| Yoshio Ishizaka Director | Nov 19, 2014 | Buy | +5,000 | $2.86 | $14.30K | 5,000 |
| Yutaka Kobayashi Director | Sep 11, 2014 | Buy | +10,000 | $2.95 | $29.50K | 25,000 |
| Yutaka Kobayashi Director | Sep 3, 2014 | Buy | +100 | $2.66 | $266 | 5,100 |
| Yutaka Kobayashi Director | Sep 3, 2014 | Buy | +5,000 | $2.63 | $13.15K | 5,000 |
| Yutaka Kobayashi Director | Sep 3, 2014 | Buy | +9,900 | $2.67 | $26.43K | 15,000 |
| Tatsuo Izumi Director | Dec 12, 2013 | Sale | −970 | $2.17 | $2.10K | 600,000 |
| Tatsuo Izumi Director | Dec 12, 2013 | Sale | −70,300 | $2.10 | $147.63K | 600,970 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.